Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07180160
Recruiting Phase 2

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

NCT07180160 · tracked via the Priya Life Science China tracker
Sponsor
Wenjin Yin
Phase
Phase 2
Started
2025-09-25
Last updated
2025-11-18

Condition(s) studied

Advanced Breast Cancer

Investigational drug(s) / intervention(s)

QL1706 →CDK4/6 inhibitorFulvestrant →

QL1706: QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).

CDK4/6 inhibitor: palbociclib OR ribociclib OR abemaciclib OR dalpiciclib

Fulvestrant: SERD

Study summary

This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Female, age≥18 years old * Expected survival ≥12 weeks * ECOG 0-1 * Pathologically confirmed recurrent or metastatic breast cancer not amenable to curative surgery * ER and/or PR positive, HER2 negative * At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1 * Previously treated with ≤2 lines chemotherapy for advanced disease; previously treated with ≤2 CDK4/6 inhibitors * Adequate organ function Exclusion Criteria: * During pregnancy and lactation * Patients with central nervous system metastasis

Primary outcome measure(s)

  • Progression-Free Survival (PFS) — From the date of starting study treatment to the date of first documentation of disease progression or death from any cause (up to approximately 1 year)
    PFS is defined as the time from the date of starting maintenance therapy to the date of disease progression or death from any cause, whichever occurs first.

Trial sites (1)

FacilityCityRegionStatus
Renji Hospital, School of Medicine, Shanghai Jiaotong University Shanghai China Recruiting

More Wenjin Yin trials in China

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer Recruiting
The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis Active, not recruiting
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer Recruiting
Trastuzumab Deruxtecan in Advanced Breast Cancer Recruiting
The Association Between Blood Routine Parameters and Breast Cancer Prognosis Active, not recruiting

Other trials for the same condition

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer Recruiting
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial Recruiting
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). Recruiting
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer Recruiting
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07180160 on ClinicalTrials.gov ↗ ← All trials in China